Biological therapy for rheumatoid arthritis: where are we now?-Reference-Cited by-同舟云学术

Biological therapy for rheumatoid arthritis: where are we now?

Published:2012-01 Issue:1 Volume:73 Page:12-18
ISSN:1750-8460
Container-title:British Journal of Hospital Medicine
language:en
Short-container-title:British Journal of Hospital Medicine

Author:

Horton Sarah C,Emery Paul¹

Affiliation:

1. Arthritis Research UK Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds LS7 4SA

Publisher

Mark Allen Group

Subject

General Medicine

Link

http://www.magonlinelibrary.com/doi/pdf/10.12968/hmed.2012.73.1.12

Reference32 articles.

1. A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

2. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

3. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

4. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?

5. Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Special considerations on interventions;Pragmatic Randomized Clinical Trials;2021

2. Better Together: Examples of Biostatisticians Collaborating in Drug Development;Quantitative Methods in Pharmaceutical Research and Development;2020

3. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology;Journal of Clinical Medicine;2019-05-14

4. Post-Authorization Safety Studies for Specialty Products;Post-Authorization Safety Studies of Medicinal Products;2018

5. New treatments for inflammatory rheumatic disease;Immunologic Research;2014-11-09